| II-66 Tobias Kanacher Development of a whole body physiologically-based pharmacokinetic (PBPK) model for inhaled salmeterol to predict interactions with CYP3A4 inhibitors Wednesday 15:50-17:20 |
| II-66 Tobias Kanacher Development of a whole body physiologically-based pharmacokinetic (PBPK) model for inhaled salmeterol to predict interactions with CYP3A4 inhibitors Wednesday 15:50-17:20 |